Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
A panel of the Ministry of Health, Labor and Welfare on December 20 approved a plan to make five-in-one combination vaccines available under the national immunization program (NIP) from April next year. In Japan, two pertussis, diphtheria, tetanus, inactivated polio,…
To read the full story
Related Article
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
- MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
November 10, 2023
- MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
August 30, 2023
- MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
April 11, 2023
REGULATORY
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…